Post by
allison5120 on Oct 24, 2021 6:10pm
ESSA has begun recruiting for its phase 1/2 combo trial
ESSA has filed an update on clinicaltrials.gov announcing that it has begun recruiting patients for its phase 1/2 combination trial (EPI-7386 and Astellas/Pfizer's Enzalutimide). This is potentially significant. Expect additional combination trials to begin end of year or Q1 2022 with J&J (Janssen) as well as Bayer.
https://clinicaltrials.gov/ct2/show/NCT05075577?term=EPI-7386&draw=1&rank=2